Indian generic drug maker Lupin Ltd. (500257.BY) said Friday its U.S. unit has received final approval from the U.S Food and Drug Administration to make and sell Lamotrigine tablets.

The approval is for tablets in strengths of 25 milligrams, 100 mg, 150 mg and 200 mg, the company said in a filing to the Bombay Stock Exchange.

Lamotrigine is the generic form of GlaxoSmithKline's (GSK) Lamictal tablets and is used for the treatment of epilepsy and bipolar disorder.

Lamotrigine tablets have annual U.S. sales of about $452 million, the company said, citing data from IMS Health market research.

-By Gurdev Singh Virk, Dow Jones Newswires; 91 22 2288 4212; gurdev.singh@dowjones.com
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Gsk Charts.
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Gsk Charts.